Strategic divestiture Recent sale of Life Sciences and Diagnostics division to 1315 Capital suggests a potential shift in strategic focus or resource redeployment. Opportunity to offer integrated scale-up, fill-finish, and packaging services to newly independent or restructured segments.

Partnership potential Active partnerships with Ensera and Bluejay Diagnostics indicate openness to collaboration on final assembly, secondary packaging, and diagnostic platforms. Target similar biotech and diagnostics firms seeking end-to-end manufacturing and packaging support.

Cybersecurity focus Ransomware incident highlights a need for strengthened data security and resilient manufacturing IT. Sell cybersecurity hardening, compliant data management, and secure cloud integration as value-added services.

Growth financing History of $45M financing and ongoing scale-up capabilities signal readiness for capacity expansion. Present messaging around scalable fill-finish capacity, regulatory-ready processes, and California expansion programs.

Technology backbone Tech stack includes AWS, SAP, iCIMS and HubSpot, indicating mature digital operations. Offer process optimization, ERP/CMC data integration, and digital transformation to improve yield, traceability, and quality systems for life sciences manufacturing.